Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents

Vision Research

Volumn 48, Issue 3, 2008, Pages 453-469

  Sullivan, Jack M ^a,b,c   Yau, Edwin H ^a   Taggart, R Thomas ^a   Butler, Mark C ^a   Kolniak, Tiffany A ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

Antisense; Gene therapy; High throughput screening; Ribozyme; RNAi; shRNA

Indexed keywords

GENE THERAPY AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PERIPHERIN; POSTTRANSCRIPTIONAL GENE SILENCING AGENT; RHODOPSIN; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; ARTICLE; DRUG TARGETING; GENE TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOCYTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; RIBOZYME THERAPY; RNA INTERFERENCE; RNA STRUCTURE;

GENE TARGETING; GENE THERAPY; HUMANS; OPSIN; RETINAL DISEASES; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 38849116446     PISSN: 00426989     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.visres.2007.09.011     Document Type: Article

References (65)

1. Allawi H.T., Dong F., Ip H.S., Neri B.P., and Lyamichev V.I. Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase. RNA 7 (2001) 314-327
2. Amarzguioui M., Brede G., Babaie E., Grøtli M., Sproat B., and Prydz H. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Research 28 (2000) 4113-4124
3. Anderson K.P., Fox M.C., Brown-Driver V., Martin M.J., and Azad R.F. Inhibition of cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrobial Agents and Chemotherapy 40 (1996) 2004-2011
4. Berger J., Hauber J., Hauber R., Geiger R., and Cullen B.R. Secreted placental alkaline phosphatase: A powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 66 (1988) 1-10
5. Bertrand E., Pictet R., and Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function?. Nucleic Acids Research 22 (1994) 293-300
6. Butler M.C., Kolniak T., and Sullivan J.M. Microscope-based high throughput cell protein quantitation for therapeutics development. Investigative Ophthalmology & Visual Science 48 (2007) 4608 (B445)
7. Butler, M.C., Kolniak, T.A., Yau, E.H., & Sullivan, J.M. (in preparation). High throughput screening and measure of cellular proteins by a quantitative immunocytochemistry imaging platform.
8. Cashman S.M., Binkley E.A., and Kumar-Singh R. Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. Gene Therapy 12 (2005) 1223-1228
9. Cashman S.M., Bowman L., Christofferson J., and Kumar-Singh R. Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Investigative Ophthalmology & Visual Science 47 6 (2006) 3496-3504
10. Daiger, S. P., Sullivan, L. S., Bowne, S. J., & Rossiter, B. J. F. (2007). RetNet. Retinal information network. (last update 5/21/2007).
11. Dalke C., Löster J., Fuchs H., Gailus-Durner V., Soewarto D., Favor J., et al. Electroretinography as a screening method for mutations causing retinal dysfunction in mice. Investigative Ophthalmology & Visual Science 45 (2004) 601-609
12. Ding Y., Chan C.Y., and Lawrence C.E. Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Research 32 (2004) W135-W141
13. Fedorov Y., Anderson E.M., Birmingham A., Reynolds A., Karpilow J., Robinson K., et al. Off-target effects by siRNA can induce toxic phenotype. RNA 12 (2006) 1188-1196
14. Haley B., and Zamore P.D. Kinetic analysis of the RNAi enzyme complex. Nature Structural Molecular Biology 11 (2004) 599-606
15. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: More isn't always better. Proceedings of the National Academy of Sciences USA 88 (1991) 6921-6925
16. Ho S.P., Bao Y., Lesher T., Malhotra R., Ma L.Y., Fluharty S.J., et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nature Biotechnology 16 (1998) 56-63
17. Hüsken D., Asselbergs F., Kinzel B., Natt F., Weiler J., Martin P., et al. mRNA fusion constructs serve in a general cell-based assay to profile oligonucleotide activity. Nucleic Acids Research 31 (2003) e102
18. Illing M.E., Rajan R.S., Bence N.F., and Kopito R.R. A rhodopsin mutant linked to retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. The Journal of Biological Chemistry 277 (2002) 34150-34160
19. Johnston J.A., Ward C.L., and Kopito R.R. Aggresomes: A cellular response to misfolded proteins. The Journal of Cell Biology 143 (1998) 1883-1898
20. Kajiwara K., Hahn L.B., Mukai S., Travis G.H., Berson E.L., and Dryja T.P. Mutations in the human retinal degeneration slow gene in autosomal dominant retinitis pigmentosa. Nature 354 (1991) 480-483
21. Kajiwara K., Sandberg M.A., Berson E.L., and Dryja T.P. A null mutation in the human peripherin/RDS gene in a family with autosomal dominant retinitis punctata albescens. Nature Genetics 3 (1993) 208-212
22. Kopito R.R. Aggresomes: Inclusion bodies and protein aggregation. Trends in Cell Biology 10 (2000) 524-530
23. Khvorova A., Lescoute A., Westhof E., and Jayasena S.D. Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nature Structural Biology 10 (2003) 708-712
24. Kiang A.-S., Palfi A., Ader M., Kenna P.F., Millington-Ward S., Clark G., et al. Toward a gene therapy for dominant disease: Validation of an RNA interference-based mutation-independent approach. Molecular Therapy 12 (2005) 555-561
25. Kolniak T., Yau E.H., Taggart R.T., and Sullivan J.M. Identification of lead candidate ribozymes for human rod opsin therapeutics. Investigative Ophthalmology & Visual Science 48 (2007) 1682 (B498)
26. Lai E., Teodoro T., and Volchuk A. Endoplasmic reticulum stress: Signaling the unfolded protein response. Physiology (Bethesda) 22 (2007) 193-201
27. Lewin A.S., Drenser K.A., Hauswirth W.W., Nishikawa S., Yasamura D., Flannery J.G., et al. Ribozyme rescue of photoreceptor cells in transgenic rat model of autosomal dominant retinitis pigmentosa. Nature Medicine 4 (1998) 967-971
28. Li T., Snyder W.K., Olsson J.E., and Dryja T.P. Transgenic mice carrying the dominant rhodopsin mutation P347S: Evidence for defective vectorial transport of rhodopsin to the outer segments. Proceedings of the National Academy of Sciences USA 93 (1996) 14176-14181
29. Lieber A., and Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Molecular and Cellular Biology 15 (1995) 540-551
30. Maksoud H.E.B.A., and Sullivan J.M. Knockdown ribozyme development for adRP gene therapy. Investigative Ophthalmology & Visual Science 44 (2003) S2340
31. Maksoud, H. E. B. A., Zuker, M., & Sullivan, J. M. (submitted for publication). Development of hammerhead ribozyme candidates against human rod opsin for retinal degeneration therapy.
32. Mathews D.H., Burkard M.E., Freier S.M., Wyatt J.R., and Turner D.H. Predicting oligonucleotide affinity to nucleic acid targets. RNA 5 (1999) 1458-1469
33. Mathews D.H. Revolutions in RNA secondary structure prediction. Journal of Molecular Biology 359 (2006) 526-532
34. McNally N., Kenna P., Humphries M.M., Hobson A.H., Khan N.W., Bush R.A., et al. Structural and functional rescue of murine rod photoreceptors by human rhodopsin transgene. Human Molecular Genetics 8 (1999) 1309-1312
35. Millington-Ward S., O'Neill B., Tuohy G., Al-Jandel N., Kiang A.S., Kenna P.F., et al. Strategems in vitro for gene therapies directed to dominant mutations. Human Molecular Genetics 6 (1997) 1415-1426
36. Naash M.I., Hollyfield J.G., Al-Ubaidi M.R., and Baehr W. Simulation of human autosomal dominant retinitis pigmentosa in transgenic mice expressing a mutated murine opsin gene. Proceedings of the National Academy of Sciences USA 90 (1993) 5499-5503
37. Nichols B.E., Sheffield V.C., Vandenburgh K., Drack A.V., et al. Butterfly-shaped pigment dystrophy of the fovea caused by a point mutation in codon 167 of the RDS gene. Nature Genetics 3 (1993) 202-207
38. Nicholson J.K., Holmes E., Lindon J.C., and Wilson I.D. The challenges of modeling mammalian biocomplexity. Nature Biotechnology 22 (2004) 1268-1274
39. Olsson J.E., Gordon J.W., Pawlyk B.S., Roof D., Hayes A., Molday R.S., et al. Transgenic mice with a rhodopsin mutation (Pro23His): A mouse model of autosomal dominant retinitis pigmentosa. Neuron 9 (1992) 815-830
40. Pan W.-H., Devlin H.F., Kelley C., Isom H.C., and Clawson G.A. A selection system for identifying accessible sites in target RNAs. RNA 7 (2001) 610-621
41. Patzel V., and Sczakiel G. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nature Biotechnology 16 (1998) 64-68
42. 2+ requirement: Importance of stem-loop II. Chembiochemistry 3 (2002) 1066-1071
43. Petrukhin K. New therapeutic targets in atrophic age-related macular degeneration. Expert Opinion on Therapeutic Targets 11 (2007) 625-639
44. Rajan R.S., Illing M.E., Bence N.F., and Kopito R.R. Specificity in intracellular protein aggregation and inclusion body formation. Proceedings of the National Academy of Sciences USA 98 (2001) 13060-13065
45. Ron D., and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews. Molecular Cell Biology 8 (2007) 519-529
46. Saliba R.S., Munro P.M., Luthert P.J., and Cheetham M.E. The cellular fate of mutant rhodopsin: Quality control, degradation and aggresome formation. Journal of Cell Science 115 (2002) 2907-2918
47. Scherr M., and Rossi J.J. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Research 26 (1998) 5079-5085
48. Scherr M., Rossi J.J., Sczakiel G., and Patzel V. RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Research 28 (2000) 2455-2461
49. Stage-Zimmermann T.K., and Uhlenbeck O.C. Hammerhead ribozyme kinetics. RNA 4 (1998) 875-889
50. Sullivan J.M. Low-cost monochromatic microsecond flash microbeam apparatus for single-cell photolysis of rhodopsin or other photolabile pigments. Review of Scientific Instruments 69 (1998) 527-539
51. Sullivan J.M., Pietras K.M., Shin B.J., and Misasi J.N. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa. Molecular Vision 8 (2002) 102-113
52. Sullivan J.M., and Taggart R.T. Novel and enhanced approaches to determine local mRNA accessibility. Investigative Ophthalmology & Visual Sciences 48 (2007) 4605 (B442)
53. Sullivan, J. M., Yau, E. H., Taggart, R. T., Butler, M. C., & Kolniak, T. A. (2007). High throughput approaches to identify and optimize lead candidate post-transcriptional gene silencing agents. Retinal Degeneration and Gene Therapy. Elsevier Conference. May 2007. Ft. Lauderdale, FL.
54. Sullivan, J. M., Yau, E. H., Taggart, R. T., & Maksoud, H. E. B. A. (in preparation). Multiparameter prediction of RNA target accessibilityL an in silico approach supports development of active hammerhead ribozymes.
55. Sung, C.-H., Schneider, B., Agarwal, N., Papermaster, D. S., Nathans, J. (1991). Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proceedings of the National Academy of Sciences USA, 88, 8840-8844.
56. Taggart, R. T., & Sullivan, J. M. (in preparation). Gene-specific, oligonucleotide-mediated competitive hybridization for determination of mRNA accessibility.
57. Tinoco Jr. I., and Bustamante C. How RNA folds. Journal of Molecular Biology 293 (1999) 271-281
58. Travis G.H., and Hepler J.E. A medley of retinal dystrophies. Nature Genetics 3 (1993) 191-192
59. Weleber R.G., Carr R.E., Murphey W.H., Sheffield V.C., and Stone E.M. Phenotypic variation including retinitis pigmentosa, pattern dystrophy, and fundus flavimaculatus in a single family with a deletion of codon 153 or 154 of the peripherin/RDS gene. Archives of Ophthalmology 111 (1993) 1531-1542
60. Wells J., Wroblewski J., Keen J., Inglehearn C., et al. Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. Nature Genetics 3 (1993) 213-218
61. Woodson S.A. Recent insights on RNA folding mechanisms from catalytic RNA. CMLS Cellular and Molecular Life Sciences 57 (2000) 796-808
62. Yau E.H., and Sullivan J.M. High throughput cellular screening for ribozyme development against arbitrary mRNA targets. Investigative Ophthalmology & Visual Science 48 (2007) 1681 (B497)
63. Yau, E. H., & Sullivan, J. M. (submitted for publication). Cell-based, high-throughput screening for therapeutic trans-cleaving ribozymes.
64. Zhang H.-Y., Mao J., Zhou D., Xu Y., Thonberg H., Liang Z., et al. mRNA accessible site tagging (MAST): A novel high throughput method for selecting effective antisense oligonucleotides. Nucleic Acids Research 31 (2003) e72
65. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Research 31 (2003) 3406-3415